(Q37812010)

23 August 2017

title

Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer (English)

1 reference

23 August 2017

Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer (English)

1 reference

https://api.crossref.org/works/10.1245/S10434-010-1401-9

2 September 2024

1 reference

1 reference

6

David L Bartlett

1 reference

23 August 2017

10

Herbert J Zeh

1 reference

23 August 2017

7

Steven J. Hughes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21104328

2 September 2024

author name string

Alyssa Krasinkas

3

1 reference

23 August 2017

Nathan Bahary

4

1 reference

23 August 2017

Philip Q. Bao

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21104328

2 September 2024

Ramesh K. Ramanathan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21104328

2 September 2024

Barry C. Lembersky

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21104328

2 September 2024

Kenneth K. Lee

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21104328

2 September 2024

A. James Moser

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21104328

2 September 2024

Herbert J. Zeh

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21104328

2 September 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21104328

2 September 2024

publication date

23 November 2010

1 reference

full work available at URL

23 August 2017

http://www.annalssurgicaloncology.org/cgi/content/abstract/18/4/1122

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21104328

http://link.springer.com/content/pdf/10.1245/s10434-010-1401-9.pdf

2 September 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1245/S10434-010-1401-9

http://link.springer.com/article/10.1245/s10434-010-1401-9/fulltext.html

2 September 2024

1 reference

https://api.crossref.org/works/10.1245/S10434-010-1401-9

http://link.springer.com/content/pdf/10.1245/s10434-010-1401-9

2 September 2024

1 reference

https://api.crossref.org/works/10.1245/S10434-010-1401-9

Annals of Surgical Oncology

2 September 2024

published in

1 reference

23 August 2017

volume

18

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

1122-1129

1 reference

Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

The ErbB signaling network: receptor heterodimerization in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

ErbB-targeted therapeutic approaches in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Epidermal growth factor receptor-targeted therapy for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1401-9

Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1245/S10434-010-1401-9

1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience

2 September 2024

2

1 reference

https://api.crossref.org/works/10.1245/S10434-010-1401-9

Gastrointestinal cancer research : GCR

2 September 2024

25

3

134

JF Sun

2009

1 reference

https://api.crossref.org/works/10.1245/S10434-010-1401-9

Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin

2 September 2024

26

1 reference

https://api.crossref.org/works/10.1245/S10434-010-1401-9

2 September 2024

Identifiers

1 reference

Dimensions Publication ID

23 August 2017

1044061716

0 references

1 reference